Outset Medical Q2 revenue $36M (+44% YoY); pauses TabloCart shipment pending 510(k) clearance

Outset Medical, Inc.

2023-Q2 EPS reported -$1.79 revenue$69,507,000

Q2 net revenue $36.0M, up 44% YoY; product revenue $29.3M (+49.5%).
Gross margin improved to 21.4% (22.5% non-GAAP) from 15.1% YoY.
Net loss $44.0M ($0.90/share) vs $43.8M ($0.92) YoY.
Paused shipment of TabloCart with Prefiltration pending FDA 510(k) clearance; plans to file later this month.
Reiterated 2023 revenue guidance $144-150M but expects low end due to pause.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Outset Medical, Inc. reported the second quarter ended June 30, 2023 results: revenue $36.0 million, net income ($44.0) million, EPS ($0.90) per share. Guidance reaffirmed.

Period: the second quarter ended June 30, 2023
Revenue: $36.0 million
Net income: ($44.0) million
EPS: ($0.90) per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

to reduce the cost and complexity of dialysis, today reported financial results for the second quarter ended June 30, 2023. Recent Highlights • Recorded net revenue of $36.0 million in the second quarter, a 44% increase compared to $25.1 million in the second quarter of 2022, and an 8% increase compared to $33.5 million in the first quarter of 2023. •

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Outset Medical, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-037134

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.